Biodesix will present interim real-world data from the Clarify study at the 2025 CHEST Annual Meeting in Chicago, including analyses from the first 1,000 patients tested with its Nodify CDT and Nodify XL2 blood-based assays for indeterminate pulmonary nodules. The company is also bringing a national assessment of healthcare resource utilization after a pulmonary nodule diagnosis, alongside multiple independent clinician-led presentations comparing Nodify results with PET/CT performance, evaluating impact on invasive procedures, and exploring use in minority communities and endemic fungal regions.
The signal here is not just another conference update; it is a deliberate push to answer the question that determines market adoption: do proteomic and autoantibody biomarkers materially change clinical decisions and reduce unnecessary downstream utilization in everyday practice? The Clarify design—a retrospective chart review targeting up to 4,000 patients with at least one year of follow-up—targets the evidence gap that payers, guideline bodies, and integrated delivery networks cite most often: clinical utility in diverse, real-world populations, not just analytical performance in controlled studies.
This matters now because pulmonary nodule detection is surging with expanded screening and incidental findings on imaging, while pulmonology and thoracic surgery capacities remain constrained. The prevailing pathway—serial imaging, PET/CT, and frequent biopsies—carries substantial cost, anxiety, and complication risk, particularly in regions where granulomatous disease inflates false positives. If Nodify can reliably reclassify risk to rule out malignancy in low-to-intermediate risk nodules without missing cancers, providers can safely de-escalate care, and systems can redirect resources to higher-risk patients. For patients, fewer unnecessary procedures and faster resolution are tangible wins. For payers, the accompanying resource utilization analysis hints at the economic argument they will expect: reductions in PET/CT scans, invasive biopsies, and OR time, validated across community and academic sites.
For competitors in lung nodule management—spanning radiomics, imaging workflows, and other molecular diagnostics—the bar is moving from technical accuracy to integrated, real-world outcomes. Independent presentations comparing Nodify XL2 to PET/CT, reporting procedure avoidance, and examining performance in underrepresented populations speak to generalizability and health equity, themes increasingly central to coverage decisions and institutional procurement. Medical Affairs teams should note the breadth of stakeholder questions this data can address: safety of surveillance in reclassified patients, time-to-diagnosis for true cancers, adherence to Fleischner and ACCP pathways, and the operational fit of blood-based testing within pulmonary and primary care workflows.
The broader trend is unmistakable. Diagnostics that claim to reshape care pathways are being judged on pragmatic evidence, not just AUCs. Payers are prioritizing hard endpoints and budget impact; guideline committees are looking for longitudinal outcomes; health systems are piloting algorithm-plus-biomarker combinations to standardize nodule management. Biodesix’s program aligns with this shift: real-world follow-up, subgroup analyses, and economic signals, timed ahead of Lung Cancer Awareness Month when screening programs amplify attention to nodules.
The next milestone is clarity on magnitude: how much risk downgrading, how many procedures avoided, and what missed cancer rate will be acceptable to move coverage and guideline language. If the full 4,000-patient dataset confirms a material reduction in invasive workups without compromising safety, expect accelerated payer adoption, system-level pathways, and potential partnerships that pair biomarkers with AI-driven radiology triage. The strategic question is whether this evidence will be sufficient to make blood-based nodule triage a default step in community practice, or whether stakeholders will demand prospective, system-wide implementation studies before resetting the standard of care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
